24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

300s Genitourinary Cancer<br />

4593 General Poster Session (Board #3H), Sun, 8:00 AM-12:00 PM<br />

Activity <strong>of</strong> intravesical CG0070 in Rb-inactive superficial bladder cancer<br />

after BCG failure: Updated results <strong>of</strong> a phase I/II trial. Presenting Author:<br />

Terence W. Friedlander, University <strong>of</strong> California, San Francisco, San<br />

Francisco, CA<br />

Background: Loss <strong>of</strong> retinoblastoma (Rb) tumor suppressor activity occurs<br />

commonly in bladder cancer and leads to upregulation <strong>of</strong> the E2F-1<br />

transcription factor. CG0070 is a replication-competent oncolytic adenovirus<br />

genetically modified to express GMCSF under control <strong>of</strong> the human<br />

E2F-1 promoter. Updated results from a phase I study <strong>of</strong> CG0070 in<br />

patients with recurrent superficial bladder cancer (T1, Ta, Tcis) after BCG<br />

treatment are presented here. Methods: The V-0046 phase I/II study<br />

previously reported the safety and evidence <strong>of</strong> efficacy <strong>of</strong> single and<br />

multiple doses <strong>of</strong> intravesical CG0070. Efficacy was determined using<br />

quarterly cystoscopy, biopsy, and/or urine cytology. Tumor Rb status was<br />

assessed immunohistochemically in 18 tumors. Results: 35 patients were<br />

treated with either a single dose (n�13) <strong>of</strong> CG0070 ranging from 1x1012 to<br />

3x1013 viral particles (vp) or with weekly x6(n�9) or every 4 week x 3-6<br />

doses (n�13) ranging from 1x1012 to 1x1013 vp per dose. The most<br />

common adverse events regardless <strong>of</strong> schedule were flu-like illness,<br />

dysuria, hematuria, bladder spasm, and nocturia. No maximum tolerated<br />

dose was reached. Urine GMCSF and CG0070 levels were detectable in<br />

almost all patients suggesting in-vivo viral replication. The CR rate in the<br />

single dose cohort was 23% (3/13), and 64% (14/22) in the multi-dose<br />

cohorts. The CR rate for patients with either CIS or Ta tumors was 65%<br />

(15/23). Of all responders, 11 recurred with a remission duration ranging<br />

from 3.0 - 33.4 months and 6 patients, all in the multiple dose cohorts,<br />

remain in remission as <strong>of</strong> last follow-up with a remission duration ranging<br />

from 3.3 – 38.2 months. Phosphorylated (inactive) Rb was detected in 13<br />

<strong>of</strong> the 18 (72%) patients evaluated. Nine <strong>of</strong> these 13 patients (70%) had a<br />

complete response. All patients (5/5, 100%) with known phosphorylated<br />

Rb treated in the weekly cohort experienced a CR. Conclusions: CG0070<br />

was well tolerated with minimal toxicities. Complete responses were more<br />

frequently observed in the multiple-dose cohorts, including durable CRs in<br />

patients with inactive Rb and in patients with CIS. Further study in<br />

Rb-inactive superficial tumors is warranted.<br />

4595 General Poster Session (Board #4B), Sun, 8:00 AM-12:00 PM<br />

Late gastrointestinal (GI) complications in patients with stage I-II testicular<br />

seminoma treated with radiotherapy (RT). Presenting Author: Christopher<br />

Leigh Hallemeier, Mayo Clinic, Rochester, MN<br />

Background: For stage I-II testicular seminoma, RT is highly effective at<br />

eradicating disease in the abdominopelvic lymph nodes, but results in<br />

unnecessary exposure to normal tissues including the GI tract. The purpose<br />

<strong>of</strong> this study was to define the incidence and risk factors for late GI<br />

complications in this patient population. Methods: A retrospective review<br />

was performed <strong>of</strong> 251 patients with stage I-II testicular seminoma treated<br />

with curative intent RT at our institution from 1974-2009. All patients<br />

underwent orchiectomy and postoperative external beam RT to the involved<br />

and/or at-risk nodal basins. Potential late GI complications that were<br />

assessed included endoscopically-confirmed gastric or duodenal ulceration,<br />

small bowel obstruction (SBO), and biopsy-confirmed malignancy <strong>of</strong><br />

the GI tract. Risks were estimated using the Kaplan-Meier (KM) technique<br />

and univariate/multivariate analyses were performed using the Cox proportional<br />

hazards model. Results: Median age at diagnosis was 36 years (range<br />

18 – 80). <strong>Clinical</strong> stage was I (n�199) or II (n�52). Median abdominopelvic<br />

RT dose was 26 Gy (interquartile range 25 – 30). Median follow-up was<br />

15 years (range 0.1 – 38). KM estimates for any GI complication (ulcer,<br />

SBO, or GI malignancy) at 10, 20, and 30 years were 7, 10 and 24%,<br />

respectively. Four patients died as result <strong>of</strong> a GI complication. KM<br />

estimates for ulcer at 10, 20, and 30 years were 4, 7, and 9%, respectively.<br />

Age at RT (Hazard Ratio [HR] 1.05, 95% Confidence Interval [CI] 1.00 –<br />

1.10, p�0.03) and RT total dose (per Gy, HR 1.20, 95% CI 1.09 – 1.31,<br />

p�0.01) were associated with risk <strong>of</strong> ulcer. KM estimates for SBO at 10,<br />

20, and 30 years were 2%, 2%, and 3%, respectively. History <strong>of</strong><br />

inflammatory bowel disease was associated with risk <strong>of</strong> SBO (HR 43, 95%<br />

CI 7-325, p�0.01). KM estimates for GI malignancy at 10, 20, and 30<br />

years were 0.5, 3 and 16%, respectively. Age at RT was associated with risk<br />

<strong>of</strong> GI malignancy (HR 1.07, 95% CI 1.02-1.14, p�0.01). Conclusions: In<br />

patients with stage I-II testicular seminoma treated with RT, late GI<br />

complications were a relatively uncommon, but clinically significant source<br />

<strong>of</strong> late morbidity. Use <strong>of</strong> low dose, limited field, and/or proton RT may<br />

reduce these risks.<br />

4594 General Poster Session (Board #4A), Sun, 8:00 AM-12:00 PM<br />

Utilization and predictors <strong>of</strong> neoadjuvant chemotherapy for muscleinvasive<br />

bladder cancer in the Veterans Health Administration. Presenting<br />

Author: Gurdarshan Singh Sandhu, Washington University School <strong>of</strong><br />

Medicine, St. Louis, MO<br />

Background: The survival benefit with neoadjuvant chemotherapy for<br />

bladder cancer was established in 2003. However, adoption <strong>of</strong> this<br />

paradigm in clinical practice has been slow. We explored the use <strong>of</strong><br />

neoadjuvant chemotherapy and identified predictors <strong>of</strong> its use in a<br />

contemporary cohort in the Veterans Health Administration (VA). Methods:<br />

Using the national VA <strong>Clinical</strong> Cancer Registry, all patients diagnosed with<br />

clinical stage T2-4, N0 or Nx, M0 bladder cancer from 1997 to 2007 were<br />

stratified into surgically (radical cystectomy [RC], n�1,211) and nonsurgically<br />

managed groups (n�2,125). Receipt <strong>of</strong> neoadjuvant chemotherapy<br />

was defined as chemotherapy treatment up to 6 months before RC as well<br />

as initial treatment only with chemotherapy (without subsequent surgery or<br />

radiation) in the nonsurgical group. Temporal trends in neoadjuvant<br />

chemotherapy use were evaluated with a chi square test. Predictors <strong>of</strong><br />

neoadjuvant chemotherapy were examined using a multivariable logistic<br />

regression model incorporating demographic, socioeconomic, comorbid,<br />

pathologic and hospital factors. Results: 6.3% and 8.3% <strong>of</strong> patients<br />

received neoadjuvant chemotherapy in the surgical and non-surgical group,<br />

respectively. Analysis <strong>of</strong> temporal trends in chemotherapy use demonstrated<br />

an increase in neoadjuvant chemotherapy use over time (p�0.0001);<br />

from 3% (2003 and before) to 14% annually (2007). On multivariable<br />

analysis <strong>of</strong> both groups, older age and more recent diagnosis were<br />

predictive <strong>of</strong> neoadjuvant chemotherapy use (Table). Other covariates did<br />

not predict receipt <strong>of</strong> neoadjuvant chemotherapy. Conclusions: While<br />

overall use <strong>of</strong> neoadjuvant chemotherapy in the VA population with bladder<br />

cancer remains low, use there<strong>of</strong> is slowly increasing, with a more recent<br />

diagnosis most strongly predicting its use.<br />

Multivariable predictors <strong>of</strong> neoadjuvant chemotherapy in bladder cancer.<br />

OR 95% CI P value<br />

Age (per year older)<br />

Year <strong>of</strong> diagnosis (reference 2003 and before)<br />

1.02 1.00-1.04 �.0001<br />

2004 1.56 0.98-2.47 0.06<br />

2005 1.23 0.76-2.00 0.39<br />

2006 1.66 1.09-2.52 0.02<br />

2007 2.38 1.59-3.57 �0.0001<br />

4596 General Poster Session (Board #4C), Sun, 8:00 AM-12:00 PM<br />

Interim results <strong>of</strong> phase II trial <strong>of</strong> the cyclin-dependent kinase 4/6 inhibitor<br />

PD-0332991 in refractory retinoblastoma protein positive germ cell<br />

tumors. Presenting Author: David J. Vaughn, Abramson Cancer Center at<br />

the University <strong>of</strong> Pennsylvania, Philadelphia, PA<br />

Background: Deregulation <strong>of</strong> the retinoblastoma pathway in germ cell<br />

tumors (GCT) has been well documented. We previously reported that<br />

PD-0332991, a selective oral inhibitor <strong>of</strong> cyclin-dependent kinase 4/6, led<br />

to prolonged disease control in 3 patients (pts) with unresectable growing<br />

teratoma syndrome (NEJM, 2009). For these reasons, we initiated a phase<br />

II trial <strong>of</strong> PD-0332991 in pts with refractory retinoblastoma protein (Rb)<br />

positive (�) GCT. Methods: Pts with incurable refractory GCT that expressed<br />

Rb by immunohistochemistry were treated with PD-0332991 125 mg<br />

orally daily for 21 days followed by a 7 day break (cycle � 28 days). Tumor<br />

assessments were performed every 2 cycles. The primary endpoint was<br />

6-month progression-free survival (PFS) rate. Results: As <strong>of</strong> 1/12/2012,<br />

archived tumors from 36 pts with refractory GCT were stained for Rb and 35<br />

had � 1� staining. 18 <strong>of</strong> planned 24 pts have been enrolled and treated.<br />

Pt characteristics: 17 male, 1 female; median age, 31 years (range,<br />

17-56); median ECOG performance status, 1 (range, 0-1); median number<br />

<strong>of</strong> prior chemotherapy regimens, 2 (range, 1-6); median number prior<br />

surgeries, 3 (range, 1-6). Pt pathology: mature teratoma (MT), 7; teratoma<br />

with malignant transformation (TMT), 7; mixed GCT, 2; late relapse (LR),<br />

2. 16 pts are evaluable; 2 pts are too early to evaluate. 5 <strong>of</strong> 16 evaluable pts<br />

achieved 6-month PFS (3 MT, 1 TMT, 1 LR). Median PFS was 2 months<br />

(range, 0-17). No objective radiological responses were observed; 7<br />

patients had best response <strong>of</strong> stable disease by RECIST criteria (3 MT, 3<br />

TMT, 1 LR). Grade 3 toxicity included neutropenia (4 pts), thrombocytopenia<br />

(3 pts), anemia (1 pt), mucositis (1 pt). No grade 4 toxicity was seen.<br />

Analysis <strong>of</strong> archival tumor for predictive biomarkers including Rb and p16<br />

expression is being performed. Conclusions: PD-0332991 has resulted in<br />

6-month PFS in pts with refractory Rb � GCT, including pts with incurable<br />

teratomas.<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!